Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 2

2246 - Clinical Confirmation of Higher Exposure to Niraparib in Tumor vs Plasma in Patients With Breast Cancer

Date

29 Sep 2019

Session

Poster Display session 2

Presenters

Laura Spring

Citation

Annals of Oncology (2019) 30 (suppl_5): v55-v98. 10.1093/annonc/mdz240

Authors

L. Spring1, M. Shan2, M.C. Liu3, E. Hamilton4, C. Santa-Maria5, H. Irie6, S. Isakoff1, J. Reeves7, L.W. Ellisen1, A. Liem8, A. Milillo Naraine9, J. Nangia10, D.B. Page11, P. Pan12, K. Sun12, J.R. Graham12, H.S. Han13

Author affiliations

  • 1 Hematology And Oncology, Massachusetts General Hospital, 02114 - Boston/US
  • 2 Clinical Science, TESARO: A GSK Company, 02451 - Waltham/US
  • 3 Oncology, Mayo Clinic Rochester, Rochester/US
  • 4 Medical Oncology, Sarah Cannon Research Institute/Tennessee Oncology, 37203 - Nashville/US
  • 5 Oncology, Sidney Kimmell Comprehensive Cancer Center at Johns Hopkins, Baltimore/US
  • 6 Medicine, Hematology And Medical Oncology, Icahn School of Medicine at Mount Sinai, New York/US
  • 7 Oncology, Florida Cancer Specialists-South, Fort Myers/US
  • 8 Hematology And Oncology, Pacific Shores Medical Group, Long Beach/US
  • 9 Medical Oncology, Memorial Health Care System, 33021 - Hollywood/US
  • 10 Medical Oncology, Baylor College of Medicine, Houston/US
  • 11 Medical Oncology, Providence Portland Medical Center, 97213 - Portland/US
  • 12 Clinical Science, TESARO: A GSK Company, Waltham/US
  • 13 Breast Oncology, Moffitt Cancer Center-McKinley Outpatient Clinic, 33612 - Tampa/US
More

Resources

Abstract 2246

Background

Niraparib is a selective oral poly(ADP-ribose) polymerase 1/2 inhibitor (PARPi) approved as maintenance treatment of recurrent ovarian cancer. Previous studies revealed unique pharmacological properties of niraparib, including a large volume of distribution, suggesting higher tissue penetration of this drug. Preclinical studies have consistently demonstrated that niraparib tumor exposure is higher than plasma exposure, whereas another PARPi, olaparib, has demonstrated lower tumor exposure than plasma exposure in tumor xenograft models. In a clinical study, tumor concentrations of olaparib were on average 41% of plasma concentrations in patients with breast cancer (BC)1. Here we report for the first time the intra-tumoral concentration of niraparib in clinical samples.

Methods

Tumor biopsies and plasma samples were collected from patients enrolled in a pilot study (NCT03329937) evaluating the antitumor activity and safety of niraparib as neoadjuvant treatment for HER2-negative, BRCA-mutated localized BC. Patients (N = 9) received oral niraparib 200 mg once daily over two 28-day cycles; 2 patients in the analysis had dose reduction to 100 mg. Biopsies and plasma were obtained at the end of Cycle 2. Additional plasma samples were collected on Cycle 2/Day 1 at 0, 2, and 4 hours post dose to determine steady-state maximum concentration (Cmax). Niraparib concentrations in plasma and tumor samples for each patient were quantified using a qualified liquid chromatography–tandem mass spectrometry method.

Results

Niraparib concentrations in plasma from patients with BC (N = 5) were within the reference range previously reported for solid tumors (steady state Cmax 3160+/-2799 nM, Ctrough 1753+/-1707 nM). In the same cohort of BC patients, niraparib concentrations in tumors ranged from approximately 4–131-fold higher than those in corresponding plasma samples after 2 months of niraparib treatment. Data for all patients will be presented at the meeting.

Conclusions

These results provide the first clinical data of at least 4-fold higher intra-tumor concentration of niraparib compared with plasma concentration in patients with BC. Reference: Bundred N et al. Invest New Drugs 2013; 31: 949-58.

Clinical trial identification

NCT03329937.

Editorial acknowledgement

Legal entity responsible for the study

Tesaro: A Gsk Company.

Funding

Tesaro: A Gsk Company.

Disclosure

M. Shan: Shareholder / Stockholder / Stock options, Full / Part-time employment: Tesaro: A GSK Company. E. Hamilton: Travel / Accommodation / Expenses: Amgen; Travel / Accommodation / Expenses: Bayer; Travel / Accommodation / Expenses: BMS; Travel / Accommodation / Expenses: Genzyme; Travel / Accommodation / Expenses: Helsinn Therapeutics; Travel / Accommodation / Expenses: HERON; Travel / Accommodation / Expenses: Lexicon; Travel / Accommodation / Expenses: Medivation; Travel / Accommodation / Expenses: Merck; Travel / Accommodation / Expenses: Novartis; Travel / Accommodation / Expenses: Roche; Travel / Accommodation / Expenses: Sysmex; Travel / Accommodation / Expenses: Guardant Health; Travel / Accommodation / Expenses: Foundation Medicine. C. Santa-Maria: Research grant / Funding (institution): Pfizer; Research grant / Funding (institution): Medimmune. S. Isakoff: Advisory / Consultancy, Research grant / Funding (institution): Abbvie; Advisory / Consultancy: Genentech/Roche; Advisory / Consultancy: PharmaMar; Research grant / Funding (institution): AstraZeneca/MedImmune; Research grant / Funding (institution): Genentech; Research grant / Funding (institution): Merck; Research grant / Funding (institution): OncoPep; Research grant / Funding (institution), Travel / Accommodation / Expenses: PharmaMar. D.B. Page: Honoraria (self): Novartis; Advisory / Consultancy: Merck Sharp & Dohme; Advisory / Consultancy: Syndax; Advisory / Consultancy: Nektar; Research grant / Funding (self): NanoString Technologies; Advisory / Consultancy, Research grant / Funding (institution), Travel / Accommodation / Expenses: Bristol-Myers Squibb; Advisory / Consultancy: Puma Biotechnology; Speaker Bureau / Expert testimony: Genentech/Roche; Research grant / Funding (institution), Travel / Accommodation / Expenses: MedImmune; Research grant / Funding (institution): Merck; Speaker Bureau / Expert testimony: Philips Healthcare. P. Pan: Shareholder / Stockholder / Stock options, Full / Part-time employment: Tesaro: A GSK Company. K. Sun: Shareholder / Stockholder / Stock options, Full / Part-time employment: Tesaro: A GSK Company. J.R. Graham: Shareholder / Stockholder / Stock options, Full / Part-time employment: Tesaro: A GSK Company. H.S. Han: Research grant / Funding (institution): Tesaro, Inc.; Research grant / Funding (institution): Novartis; Research grant / Funding (institution): BMS; Research grant / Funding (institution): Pfizer; Research grant / Funding (institution): Prescient; Research grant / Funding (institution): Horizon; Research grant / Funding (institution): Karyopharm; Research grant / Funding (institution): Abbvie; Research grant / Funding (institution): TapImmune; Research grant / Funding (institution): Ipsen; Research grant / Funding (institution): Seattle Genetics; Research grant / Funding (institution): Department of Defense. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings